Stock Events

Stock Events

Compugen 

$2.34
81
-$0.07-2.9% 16:23 Today

Statistics

Day High
2.4
Day Low
2.34
52W High
3.24
52W Low
1.3
Volume
130,183
Avg. Volume
366,391
Mkt Cap
221.34M
P/E Ratio
6.29
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.08
0.14
0.37
0.6
Expected EPS
-0.08
Actual EPS
N/A

Financials

48.57%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
72.76MRevenue
35.34MNet Income

Analyst Ratings

5.50Average Price Target
The highest estimate is 6.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CGEN. It's not an investment recommendation.
NVIDIA
22
NVDA
Amazon
20
AMZN
AMD
19
AMD
Apple
18
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap24.36B
Incyte Corporation operates in the same biopharmaceutical space, focusing on the discovery, development, and commercialization of proprietary therapeutics, similar to Compugen's work in cancer immunotherapy.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals is a competitor due to its extensive work in the development of monoclonal antibodies for the treatment of cancer, among other diseases, which competes with Compugen's therapeutic development.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotechnology pioneer that discovers, develops, manufactures, and delivers innovative human therapeutics, including treatments in oncology, which competes with Compugen's cancer immunotherapy research.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is a global healthcare company that produces pharmaceutical products, including cancer treatments, directly competing with Compugen's focus on cancer immunotherapy.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb is involved in the discovery, development, and delivery of medicines for cancer and other diseases, making it a direct competitor to Compugen in the oncology space.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. is a global pharmaceutical corporation that develops and manufactures healthcare products, including oncology drugs, competing with Compugen's cancer treatment research.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, including oncology, competing with Compugen's focus.
Novartis
NVS
Mkt Cap286.78B
Novartis AG is a global healthcare company that provides solutions to address the evolving needs of patients worldwide, including in oncology, making it a competitor to Compugen.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is a global healthcare leader that works to discover and bring life-changing medicines to those who need them, including cancer treatments, competing with Compugen's therapeutic development.

About

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Show more...
CEO
Eran Ophir
Employees
75
Country
Israel
ISIN
IL0010852080

Listings

XNAS
US
CGEN
TA
IL
CGEN.TA
BOATS
BOATS
CGEN.BOATS

0 Comments

Share your thoughts

FAQ

What is Compugen stock price today?▼
The current price of CGEN is $2.34 USD — it has decreased by -2.9% in the past 24 hours. Watch Compugen stock price performance more closely on the chart.
What is Compugen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Compugen stocks are traded under the ticker CGEN.
Is Compugen stock price growing?▼
CGEN stock has risen by +1.07% compared to the previous week, the month change is a -0.21% fall, over the last year Compugen has showed a +65.38% increase.
What is Compugen market cap?▼
Today Compugen has the market capitalization of 221.34M
When is the next Compugen earnings date?▼
Compugen is going to release the next earnings report on November 16, 2026.
What were Compugen earnings last quarter?▼
CGEN earnings for the last quarter are -0.07 USD per share, whereas the estimation was -0.08 USD resulting in a +12.52% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Compugen revenue for the last year?▼
Compugen revenue for the last year amounts to 72.76M USD.
What is Compugen net income for the last year?▼
CGEN net income for the last year is 35.34M USD.
How many employees does Compugen have?▼
As of August 17, 2026, the company has 75 employees.
In which sector is Compugen located?▼
Compugen operates in the Health & Wellness sector.
When did Compugen complete a stock split?▼
Compugen has not had any recent stock splits.
Where is Compugen headquartered?▼
Compugen is headquartered in Holon, Israel.